ACADIA Pharmaceuticals Inc.
ACADHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company carries a $3.71B market cap, placing it firmly in the mid-cap category. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Market Cap
$3.71B
Beta
0.86
P/E (TTM)
9.80
P/E (Fwd)
24.26
EPS (TTM)
$2.21
EPS (Fwd)
$0.89
ROE
37.3%
ROA
3.7%
Cash
$851.5M
Total Debt
$50.8M
Free CF
$154.1M
52W Change
0.9%
Annual Financials
Cash vs Debt
With $851.5M in cash and $50.8M in debt, ACAD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $154.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 37.3%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $517.2M (2022) to $1.07B (2025), reflecting a 107% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence ACADIA Pharmaceuticals Inc.'s trajectory.